These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34864494)

  • 1. Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery-A systematic review and meta-analysis.
    O'Connor DJ; Davey MG; Barkley LR; Kerin MJ
    Breast; 2022 Feb; 61():1-10. PubMed ID: 34864494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer.
    Truin W; Vugts G; Roumen RM; Maaskant-Braat AJ; Nieuwenhuijzen GA; van der Heiden-van der Loo M; Tjan-Heijnen VC; Voogd AC
    Ann Surg Oncol; 2016 Jan; 23(1):51-7. PubMed ID: 25980321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer.
    Petrelli F; Barni S
    Breast Cancer Res Treat; 2013 Nov; 142(2):227-35. PubMed ID: 24177758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.
    Delpech Y; Coutant C; Hsu L; Barranger E; Iwamoto T; Barcenas CH; Hortobagyi GN; Rouzier R; Esteva FJ; Pusztai L
    Br J Cancer; 2013 Feb; 108(2):285-91. PubMed ID: 23299541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
    Lips EH; Mukhtar RA; Yau C; de Ronde JJ; Livasy C; Carey LA; Loo CE; Vrancken-Peeters MJ; Sonke GS; Berry DA; Van't Veer LJ; Esserman LJ; Wesseling J; Rodenhuis S; Shelley Hwang E;
    Breast Cancer Res Treat; 2012 Nov; 136(1):35-43. PubMed ID: 22961065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.
    Cocquyt VF; Blondeel PN; Depypere HT; Praet MM; Schelfhout VR; Silva OE; Hurley J; Serreyn RF; Daems KK; Van Belle SJ
    Eur J Surg Oncol; 2003 May; 29(4):361-7. PubMed ID: 12711290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with invasive lobular breast cancer are less likely to undergo breast-conserving surgery: a population based study in the Netherlands.
    Truin W; Roumen RM; Siesling S; van der Heiden-van der Loo M; Duijm LE; Tjan-Heijnen VC; Voogd AC
    Ann Surg Oncol; 2015 May; 22(5):1471-8. PubMed ID: 25323475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.
    Petruolo OA; Pilewskie M; Patil S; Barrio AV; Stempel M; Wen HY; Morrow M
    Ann Surg Oncol; 2017 Sep; 24(9):2556-2562. PubMed ID: 28560596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical management of lobular carcinoma from a national screening program: a retrospective analysis.
    Sharma SD; Barry M; O'Reilly EA; Kell MR
    Eur J Surg Oncol; 2015 Jan; 41(1):79-85. PubMed ID: 25441933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating Surgical Outcomes Between Estrogen Receptor Positive Invasive Lobular and Invasive Ductal Carcinoma of the Breast-A Propensity Matched Analysis.
    O'Connor DJ; Davey MG; McFeetors C; McLaughlin RP; Sweeney KJ; Barry MK; Malone CM; Wahab SAE; Lowery AJ; Kerin MJ
    Clin Breast Cancer; 2024 Jun; ():. PubMed ID: 39127596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
    Wenzel C; Bartsch R; Hussian D; Pluschnig U; Altorjai G; Zielinski CC; Lang A; Haid A; Jakesz R; Gnant M; Steger GG
    Breast Cancer Res Treat; 2007 Jul; 104(1):109-14. PubMed ID: 17061042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rate of re-excision after breast-conserving surgery for invasive lobular carcinoma.
    Wanis ML; Wong JA; Rodriguez S; Wong JM; Jabo B; Ashok A; Lum SS; Solomon NL; Reeves ME; Garberoglio CA; Senthil M
    Am Surg; 2013 Oct; 79(10):1119-22. PubMed ID: 24160812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy in breast-conserving surgery - Consequences on margin status and excision volumes: A nationwide pathology study.
    Volders JH; Haloua MH; Krekel NM; Negenborn VL; Barbé E; Sietses C; Jóźwiak K; Meijer S; van den Tol MP;
    Eur J Surg Oncol; 2016 Jul; 42(7):986-93. PubMed ID: 27211343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile.
    Mathieu MC; Rouzier R; Llombart-Cussac A; Sideris L; Koscielny S; Travagli JP; Contesso G; Delaloge S; Spielmann M
    Eur J Cancer; 2004 Feb; 40(3):342-51. PubMed ID: 14746851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast surgery after neoadjuvant chemotherapy in patients with lobular carcinoma: surgical and oncologic outcome.
    van Hemert A; van Loevezijn AA; Bosman A; Vlahu CA; Loo CE; Peeters MTFDV; van Duijnhoven FH; van der Ploeg IMC
    Breast Cancer Res Treat; 2024 Apr; 204(3):497-507. PubMed ID: 38189904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study.
    Wang K; Zhu GQ; Shi Y; Li ZY; Zhang X; Li HY
    Clin Breast Cancer; 2019 Feb; 19(1):e101-e115. PubMed ID: 30502219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB).
    Rothschild HT; Clelland EN; Abel MK; Chien AJ; Shui AM; Esserman L; Khan SA; Mukhtar RA
    Breast Cancer Res Treat; 2024 Jan; 203(2):245-256. PubMed ID: 37833450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do non-classic invasive lobular carcinomas derive a benefit from neoadjuvant chemotherapy?
    Mamtani A; Grabenstetter A; Sevilimedu V; Morrow M; Gemignani ML
    Breast Cancer Res Treat; 2023 Jan; 197(2):417-423. PubMed ID: 36394689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
    Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
    Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
    Moran MS; Yang Q; Haffty BG
    Breast J; 2009; 15(6):571-8. PubMed ID: 19995377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.